39 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
.
Tourmaline also continued to expand its executive leadership team during 2023, including the appointments of Gerhard Hagn as SVP, Head of Commercial
8-K
EX-99.1
TRML
Tourmaline Bio Inc
8 Jan 24
Regulation FD Disclosure
9:19am
transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases
Experienced leadership team 4 Ryan … trial also expected to commence in H2 2024 Accomplished leadership team: extensive experience developing and commercializing antibodies for immune
8-K
EX-99.1
7owtuoz
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
8-K
5uzdaxu461
19 Oct 23
Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million
9:11pm
425
2oggsd4c
26 Sep 23
Business combination disclosure
8:24am
8-K
EX-99.1
ahqbhg418d3h2eie
26 Sep 23
Regulation FD Disclosure
8:21am
424B3
bzyc6 y3entq4hy
15 Sep 23
Prospectus supplement
6:31am
425
gsswu gwp0dd
13 Sep 23
Business combination disclosure
9:14am
8-K
EX-99.1
lgtwv9lck5pja3p wj
13 Sep 23
Regulation FD Disclosure
9:13am
S-4/A
za28kn iq59sbdo1l
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
f9xebzzfhe
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
n1b729fo hi8mbu29fg
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-99.2
1v2 b2kta
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am